Price Alert: Shares of Titan Medical (TMDI) Trade 5.22% Higher at Midday August 4

Equities Staff  |

Shares of Titan Medical Inc (NASDAQ: TMDI) climbed 5.22% Thursday.

As of 12:08:39 est, Titan Medical sits at $0.57 and has climbed $0.0282 per share.

Titan Medical has moved 3.01% over the last 30 days and has a YTD change of 13.50% based on the previous close.

The company anticipates its next earnings on 2022-08-11.

For technical charts, analysis, and more on Titan Medical visit the company profile.

About Titan Medical Inc

Titan Medical Inc. is focused on robotic-assisted technologies for application in minimally invasive surgery (“MIS”). Enos, by Titan Medical, is being developed to become the new standard of care in robotic single access surgery, and comprises a surgeon-controlled patient cart that includes a dual-view camera system with 3D and 2D high-definition vision systems and multi-articulating instruments for performing MIS procedures, and a surgeon workstation that provides an ergonomic interface to the MIS procedure performed through the patient cart. With the Enos system, Titan intends to initially pursue gynecologic surgical indications.

To get more information on Titan Medical Inc and to follow the company's latest updates, you can visit the company's profile page here: Titan Medical Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

The Strong Dollar Is a Problem for Stocks
3 Ways Finance Teams Can Navigate Inflation Through Automation



Market Movers

Sponsored Financial Content